Invest, Acquire, Partner & Collaborate to Enhance Targeted Cell Depletion
September 22-23 | Boston, MA
Driving deal-making across targeted cell depletion, checkpoint agonism, tolerance, and oral anti-inflammatory biologics to differentiate, validate, raise capital, and accelerate more durable treatments for autoimmune disease
Confirmed to Attend:
Why Attend?
Returning for its second year, the Autoimmunity & Inflammation Partnering & Investment Summit unites over 80 on-scope and in-strategy companies to increase your success rate, efficiency, and collaborative outcomes.
Unite to:
- Capitalize on protected face-to-face networking with a 100% aligned audience and the One-on-One Partnering system, to efficiently generate higher-yielding deal opportunities and nurture multiple key relationships in a less competitive forum
- Understand assessment criteria, data package expectations, and due diligence of pharma and investors, and hear invaluable feedback into your financing or development programs
- Evaluate the total landscape of emerging assets to discuss collaboration and licensing options with similar stakeholders seeking creative partnerships to validate technologies or de-risk asset development
EXPERT SPEAKERS INCLUDE
Networking Format
Pharma & Investor Icebreaker Sessions
Understand Interests Ahead of Meetings, to Present Insights Buyers Want
Don’t miss opening pharma and investor icebreaker panels where Immunology Search & Evaluation, and Investment leads share context into expectations for data packages, stage of assets, targets of interest, and future deal-making trends. Understand nuances between buyers’ interests to see who you align best with or start your 1-to-1 meeting from an advantage point, leading with information that matches these insights into buyers’ interests
Individual Meetings: One-on-One Partnering™
Schedule Meetings in Advance, with the Industry’s Best Partnering Portal
Prepare and pre-arrange your most important meetings by reviewing the full attendee list, and company profiles and reaching out to fill your meeting calendar in advance. Guarantee 30-minute, 1-2-1, and face-to-face time, with pharma present in 70% of meetings and a 30% acceptance rate versus industry standard*
*Statistics an average from 2024 and 2025 Partnering & Investment Summits by Hanson Wade
Testimonials
“This was a brilliant opportunity to connect with potential partners and hear meaningful talks and discussions relevant to the space."
“The event assembled a diverse set of stakeholders extremely relevant in ADC & RLT partnering, including pharma BD, investors, and biotech executives. It was the right size (~100 attendees) that created organic opportunities for connections”